{"DataElement":{"publicId":"6290094","version":"1","preferredName":"Liquid Enzalutamide Formulation Encounter Usage Problem Text","preferredDefinition":"Text description of the problem encountered with the use of the liquid enzalutamide formulation.","longName":"EZLTMD_LQ_PROB_TXT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6289623","version":"1","preferredName":"Liquid Dosage Form Enzalutamide Encounter Use Problem","preferredDefinition":"A state of substance that is an intermediate one entered into as matter goes from solid to gas; liquids are also intermediate in that they have neither the orderliness of a crystal nor the randomness of a gas. (Note: This term should not be used to describe solutions, only pure chemicals in their liquid state.)_An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance._Each individual, unique interaction between two subjects of interest._A manner, or usual, or accepted practice of using something._A difficulty, disorder, or condition needing resolution.","longName":"6289595v1.0:6289621v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"6289595","version":"1","preferredName":"Liquid Dosage Form Enzalutamide","preferredDefinition":"A state of substance that is an intermediate one entered into as matter goes from solid to gas; liquids are also intermediate in that they have neither the orderliness of a crystal nor the randomness of a gas. (Note: This term should not be used to describe solutions, only pure chemicals in their liquid state.):An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","longName":"C42953:C71744","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liquid Dosage Form","conceptCode":"C42953","definition":"A substance in the fluid state of matter having no fixed shape but a fixed volume.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Enzalutamide","conceptCode":"C71744","definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C53345D-21C0-5FD8-E053-F662850AB836","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"ONEDATA","dateModified":"2018-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6289621","version":"1","preferredName":"Encounter Use Problem","preferredDefinition":"Each individual, unique interaction between two subjects of interest.:A manner, or usual, or accepted practice of using something.:A difficulty, disorder, or condition needing resolution.","longName":"C62143:C25340:C28020","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Encounter","conceptCode":"C62143","definition":"Each individual, unique interaction between two subjects of interest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Use","conceptCode":"C25340","definition":"A manner, or usual, or accepted practice of using something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Problem","conceptCode":"C28020","definition":"A difficulty, disorder, or condition needing resolution.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C53A309-0F5A-2683-E053-F662850ABB4A","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"ONEDATA","dateModified":"2018-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C53A309-0F6B-2683-E053-F662850ABB4A","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"COOPERM","dateModified":"2018-05-17","changeDescription":"Created for 18C0070 Tolerability Assessment of Liquid 5.10.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017223","version":"1","preferredName":"Descriptive 100 Character Text","preferredDefinition":"Text entry of 100 character maximum length.","longName":"DESC_100_TXT","context":"CCR","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B0D0BF-9D82-627A-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-26","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-26","modifiedBy":"REEVESD","dateModified":"2006-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If yes, please describe what","type":"Preferred Question Text","description":"If yes, please describe what problems you encountered:","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C578161-827E-3360-E053-F662850A75C7","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"COOPERM","dateModified":"2018-05-17","changeDescription":"Created for 18C0070 Tolerability Assessment of Liquid 5.10.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}